That's the gap the NIH Helping to End Addiction Long-term (HEAL) Initiative was built to close.
A $3.9 Billion Commitment to a Different Future
The results are starting to show. U.S. overdose deaths dropped 4% between 2022 and 2023. Provisional data through September 2024 shows a remarkable 24% decline. These numbers don't happen by accident.
The Non-Opioid Renaissance Is Here
In the chronic pain space, the HEAL-funded Phase 2b trial of nispomeben — a first-in-class kinase inhibitor targeting painful diabetic peripheral neuropathy — completed enrollment in 2025. This molecule has zero binding affinity for opioid, serotonin, GABA, or cannabinoid receptors. It works through an entirely novel intracellular mechanism (Lyn kinase/P2X4 pathway), and if validated, it could fundamentally change how we treat metabolic neuropathies.
The pipeline doesn't stop there. ENT1 inhibitors from Duke University show accumulating analgesic efficacy over time — the pharmacological opposite of opioid tolerance. Implantable local analgesic polymers are entering pivotal trials for post-surgical pain. The first clinic-ready monoclonal antibody against fentanyl has received FDA fast-track designation.
Beyond Drugs: Biomarkers, Devices, and Digital Therapeutics
On the device side, peripheral nerve stimulation systems show 70% responder rates and an average pain reduction of 63%. Researchers are developing injectable electrode materials that solidify around target nerves, eliminating the need for surgical implantation. Non-invasive focused ultrasound technologies are achieving sustained reductions in pain and craving, lasting up to 90 days.
And VR therapy has crossed from novelty to clinical legitimacy. fMRI data show that immersive VR doesn't just distract — it neurobiologically dampens activity in the insular and somatosensory cortices, mimicking the analgesic effects of systemic opioids without the risks. An FDA-cleared VR therapy for chronic pain reached commercialization in 2025 with HEAL support.
The Biopsychosocial Mandate
Two principles embedded in this framework deserve special attention from practicing clinicians. First, HEAL now mandates the integration of People with Lived Experience (PWLE) throughout the research lifecycle — in study design, endpoint selection, and data dissemination. Outcomes are being measured by what actually matters to patients: sleep quality, functional mobility, mood stabilization — not just arbitrary numeric pain scores.
Second, the initiative's emphasis on community-embedded pragmatic trials reflects a hard-earned recognition that therapies proven in well-resourced academic settings often fail in the real world. Implementation science — the study of how to actually deploy evidence-based care in chaotic, under-resourced healthcare systems — has moved from afterthought to core priority.
What This Means for Clinicians Right Now
For clinicians on the front lines, the takeaway is clear: the future of pain management is multimodal, mechanism-based, and patient-centered. It demands that we move beyond the false binary of "opioids vs. nothing" and toward integrated care models that address the full biopsychosocial reality of persistent pain.
Initiatives like HEAL create the evidence base. But translating that evidence into practice requires infrastructure, education, and clinical frameworks that meet providers and patients where they are.
Where Anodunos Fits
Our Anodunos Method Navigator (AMN) and Anodunos Method Provider (AMP) certification programs train healthcare professionals in the integrative, whole-person approach to chronic pain that HEAL's own strategic priorities now mandate. The U.S. Pain Foundation — whose rallying cry, "Nothing About Us, Without Us," has become a defining principle in patient advocacy — reflects the same commitment to centering people with lived experience that HEAL has now embedded as a core research requirement.
The science is moving in the right direction. What the field needs now — and what programs like ours are designed to deliver — is the bridge between breakthrough research and the exam room, the telehealth screen, and the community health center where 50 million Americans are waiting for better answers.
A $3.9 Billion Commitment to a Different Future
Launched in 2018 and administered jointly by NINDS and NIDA, the HEAL Initiative has grown into one of the most ambitious biomedical research endeavors in the world — more than 2,200 active projects across all 50 states, over 8,000 peer-reviewed publications, and more than 40 investigational new drug or device designations advanced through the FDA.
The results are starting to show. U.S. overdose deaths dropped 4% between 2022 and 2023. Provisional data through September 2024 shows a remarkable 24% decline. These numbers don't happen by accident.
The Non-Opioid Renaissance Is Here
In early 2025, the FDA approved suzetrigine (Journavx) — the first entirely new class of non-opioid analgesic for moderate-to-severe acute pain in over 15 years. The drug selectively inhibits the NaV1.8 sodium channel, blocking nociceptive signal transmission in the peripheral nervous system without triggering the respiratory depression, cognitive impairment, or addiction pathways associated with opioids. Prescription rates more than doubled between April and August 2025.
In the chronic pain space, the HEAL-funded Phase 2b trial of nispomeben — a first-in-class kinase inhibitor targeting painful diabetic peripheral neuropathy — completed enrollment in 2025. This molecule has zero binding affinity for opioid, serotonin, GABA, or cannabinoid receptors. It works through an entirely novel intracellular mechanism (Lyn kinase/P2X4 pathway), and if validated, it could fundamentally change how we treat metabolic neuropathies.
The pipeline doesn't stop there. ENT1 inhibitors from Duke University show accumulating analgesic efficacy over time — the pharmacological opposite of opioid tolerance. Implantable local analgesic polymers are entering pivotal trials for post-surgical pain. The first clinic-ready monoclonal antibody against fentanyl has received FDA fast-track designation.
Beyond Drugs: Biomarkers, Devices, and Digital Therapeutics
Perhaps the most transformative aspect of HEAL is its insistence that chronic pain is not a monolithic diagnosis. The BACPAC Research Program has demonstrated that patients reporting identical pain scores can exhibit drastically different biological, biomechanical, and behavioral profiles. Using dynamic biplane radiography, plasma cytokine profiling, genetic mapping, and AI-driven data integration, BACPAC is pioneering precision medicine for chronic low back pain — matching interventions to individual phenotypes rather than applying one-size-fits-all protocols.
On the device side, peripheral nerve stimulation systems show 70% responder rates and an average pain reduction of 63%. Researchers are developing injectable electrode materials that solidify around target nerves, eliminating the need for surgical implantation. Non-invasive focused ultrasound technologies are achieving sustained reductions in pain and craving, lasting up to 90 days.
And VR therapy has crossed from novelty to clinical legitimacy. fMRI data show that immersive VR doesn't just distract — it neurobiologically dampens activity in the insular and somatosensory cortices, mimicking the analgesic effects of systemic opioids without the risks. An FDA-cleared VR therapy for chronic pain reached commercialization in 2025 with HEAL support.
The Biopsychosocial Mandate
HEAL's 2025–2030 strategic framework reclassifies pain as a complex biopsychosocial phenomenon, aligning with updated IASP definitions. Ten strategic research priorities now guide all funding — from deepening our understanding of human pain biology to halting the acute-to-chronic transition, addressing health disparities, and advancing personalized, multimodal treatment combinations.
Two principles embedded in this framework deserve special attention from practicing clinicians. First, HEAL now mandates the integration of People with Lived Experience (PWLE) throughout the research lifecycle — in study design, endpoint selection, and data dissemination. Outcomes are being measured by what actually matters to patients: sleep quality, functional mobility, mood stabilization — not just arbitrary numeric pain scores.
Second, the initiative's emphasis on community-embedded pragmatic trials reflects a hard-earned recognition that therapies proven in well-resourced academic settings often fail in the real world. Implementation science — the study of how to actually deploy evidence-based care in chaotic, under-resourced healthcare systems — has moved from afterthought to core priority.
What This Means for Clinicians Right Now
The HEAL Initiative isn't just a research program. It's a signal — to payers, to health systems, to every provider still navigating the impossible space between undertreating pain and overprescribing opioids — that the science is finally catching up to the complexity of the problem.
For clinicians on the front lines, the takeaway is clear: the future of pain management is multimodal, mechanism-based, and patient-centered. It demands that we move beyond the false binary of "opioids vs. nothing" and toward integrated care models that address the full biopsychosocial reality of persistent pain.
Initiatives like HEAL create the evidence base. But translating that evidence into practice requires infrastructure, education, and clinical frameworks that meet providers and patients where they are.
Where Anodunos Fits
This is precisely the space where our work at Anodunos operates. While the HEAL Initiative is generating groundbreaking science at the molecular, device, and behavioral levels, Anodunos is building the clinical education and patient navigation infrastructure needed to translate these advances into real-world practice.
Our Anodunos Method Navigator (AMN) and Anodunos Method Provider (AMP) certification programs train healthcare professionals in the integrative, whole-person approach to chronic pain that HEAL's own strategic priorities now mandate. The U.S. Pain Foundation — whose rallying cry, "Nothing About Us, Without Us," has become a defining principle in patient advocacy — reflects the same commitment to centering people with lived experience that HEAL has now embedded as a core research requirement.
The science is moving in the right direction. What the field needs now — and what programs like ours are designed to deliver — is the bridge between breakthrough research and the exam room, the telehealth screen, and the community health center where 50 million Americans are waiting for better answers.
The Anodunos Method
Quick links
Created with
